Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Expert Rev Pharmacoecon Outcomes Res ; 19(5): 609-617, 2019 Oct.
Article in English | MEDLINE | ID: mdl-30758237

ABSTRACT

Background: Sunitinib and Pazopanib are two metastatic renal cell carcinoma (MRCC) treatment alternatives, however the health system in Chile does not consider coverage for any. The cost-effectiveness versus relevant comparator was assessed to support evidence-based decision making. Methods: A four health states Markov model was built: first, second line treatments, BSC and death. Benefits were measured in QALYs, and efficacy estimates were obtained from an indirect treatment comparison. A 10-year time horizon and a 3% undifferentiated discount rate were considered. Deterministic and probabilistic sensitivity analyses were performed. Results: The costs of treating MRCC with Sunitinib were higher than Pazopanib and BSC. When comparing Sunitinib versus Pazopanib, the incremental benefit is small favoring Sunitinib (0.03 QALYs). The base case scenario shows an average ICER of PA versus BSC of US$62,327.11/QALY and of US$85,885/QALY for Sunitinib versus Pazopanib. The ICER was most sensitive to the OS relative to BSC, where evidence was associated to important bias. Conclusions: Sunitinib or Pazopanib can be considered cost-effective if a 3 GDP per-capita threshold is assumed. The decision between SU or PA is highly sensitive to the price of the drugs, rather than the outcomes. Therefore, the decision might be made based on cost-minimization exercise.


Subject(s)
Carcinoma, Renal Cell/drug therapy , Kidney Neoplasms/drug therapy , Pyrimidines/administration & dosage , Sulfonamides/administration & dosage , Sunitinib/administration & dosage , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/economics , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/economics , Carcinoma, Renal Cell/economics , Carcinoma, Renal Cell/pathology , Chile , Cost-Benefit Analysis , Decision Making , Drug Costs , Evidence-Based Medicine , Health Status , Humans , Indazoles , Kidney Neoplasms/economics , Kidney Neoplasms/pathology , Markov Chains , Models, Economic , Neoplasm Metastasis , Pyrimidines/economics , Quality-Adjusted Life Years , Sulfonamides/economics , Sunitinib/economics
3.
Value Health Reg Issues ; 14: 28-32, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29254538

ABSTRACT

OBJECTIVES: To assess the impact on the 2015 national health budget of incorporating Daclatasvir/Asunaprevir (DCV / ASV) for the treatment of Hepatitis C genotype 1b (HC1b) in Chile. METHODS: A Chilean HC1b patients cohort was modelled using local prevalence and incidence data. Two scenarios were built and compared, one were all patients receive Peginterferon/Ribavirin (PR) and another were all patients are treated with DCV/ASV. The analysis was conducted from the perspective of public health system of Chile assuming 100% reimbursement and a time horizon of 5 years. Costs associated with drug treatment, adverse events, other relevant resources and costs associated with disease complications were used. RESULTS: At a total DCV/ASV treatment price of USD $55,039, an additional of USD $65,6MM are required during the first year (prevalent cases) equivalent to 0.71% of the 2015 national health budget. From year 2 (incident cases), an additional of USD $12,3MM are needed (0.13% of the 2015 health budget). A price reduction of 33% (USD $36,693), requires an additional of USD $38,2MM the first year and USD $7,16MM from the second year (0.11% and 0.6% of the health budget). If the treatment price is reduced further (USD $18,347), an additional USD $10,9MM are required for the first year and USD $2,03MM from the second year (0.3% and 0.057% of the 2015 heath budget). CONCLUSION: The impact on the health budget ranges between 0.3% and 0.71% the first year and decreases to less than 0.15% from the second year considering the price assessed price range.


Subject(s)
Antiviral Agents/therapeutic use , Cost-Benefit Analysis , Drug Therapy, Combination , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/economics , Public Health , Antiviral Agents/economics , Carbamates , Chile/epidemiology , Cohort Studies , Genotype , Hepacivirus/genetics , Hepacivirus/physiology , Hepatitis C, Chronic/epidemiology , Humans , Imidazoles , Interferon-alpha/therapeutic use , Isoquinolines , Polyethylene Glycols/therapeutic use , Protease Inhibitors , Pyrrolidines , Recombinant Proteins/therapeutic use , Ribavirin/therapeutic use , Sulfonamides , Valine/analogs & derivatives
4.
Med Oral Patol Oral Cir Bucal ; 22(6): e694-e701, 2017 Nov 01.
Article in English | MEDLINE | ID: mdl-29053653

ABSTRACT

BACKGROUND: The objective of this study was to assess the potential clinical value of the concentration of soluble salivary E-cadherin (sE-cadherin) compared with the clinical value of the presence of membranous E-cadherin (mE-cadherin) in oral squamous cell carcinoma tumor tissues. MATERIAL AND METHODS: Data regarding patient demographics, clinical stage, saliva and tumor tissue samples were collected. The saliva was analyzed for sE-cadherin protein levels and was compared to the mE-cadherin immunohistochemical expression levels in tumor tissues, which were assessed via the HercepTest® method. Patients without cancer were included in the study as a control group for comparisons of the sE-cadherin levels. RESULTS: sE-cadherin levels in the saliva of patients without cancer were lower than those in patients with cancer, and the difference was statistically significant (p=0.031). Low mE-cadherin expression was statistically significantly associated with lymph node positivity (p=0.015) and advanced clinical stage (p=0.001). The inverse relationship between mE-cadherin and sE-cadherin was significant in terms of lymph node positivity (p=0.014) and advanced clinical stage (p=0.037). CONCLUSIONS: The results suggest that sE-cadherin levels are significantly increased in patients with oral cancer and that its low expression within the membrane as well as the progression of the disease appear to be inversely associated with levels of sE-cadherin in the saliva.


Subject(s)
Cadherins/analysis , Carcinoma, Squamous Cell/chemistry , Mouth Neoplasms/chemistry , Saliva/chemistry , Carcinoma, Squamous Cell/pathology , Female , Humans , Male , Middle Aged , Mouth Neoplasms/pathology , Neoplasm Staging
5.
Genome Announc ; 4(6)2016 Nov 10.
Article in English | MEDLINE | ID: mdl-27834708

ABSTRACT

We report the complete genome sequence of the first Mexican human coronavirus (HCoV) OC43, obtained by new-generation sequencing and a metagenomic approach, isolated from a child hospitalized with pneumonia. The genome is closely related to the other OC43 genome sequences available, ranging from 99.8% to 98.2% nucleotide sequence identity.

6.
Med Oral Patol Oral Cir Bucal ; 21(5): e637-43, 2016 Sep 01.
Article in English | MEDLINE | ID: mdl-27475688

ABSTRACT

BACKGROUND: Preemptive analgesia is considered an alternative for treating the postsurgical pain of third molar removal. The aim of this study was to evaluate the preemptive analgesic efficacy of oral ketorolac versus intramuscular tramadol after a mandibular third molar surgery. MATERIAL AND METHODS: A parallel, double-blind, randomized, placebo-controlled clinical trial was carried out. Thirty patients were randomized into two treatment groups using a series of random numbers: Group A, oral ketorolac 10 mg plus intramuscular placebo (1 mL saline solution); or Group B, oral placebo (similar tablet to oral ketorolac) plus intramuscular tramadol 50 mg diluted in 1 mL saline solution. These treatments were given 30 min before the surgery. We evaluated the time of first analgesic rescue medication, pain intensity, total analgesic consumption and adverse effects. RESULTS: Patients taking oral ketorolac had longer time of analgesic covering and less postoperative pain when compared with patients receiving intramuscular tramadol. CONCLUSIONS: According to the VAS and UAC results, this study suggests that 10 mg of oral ketorolac had superior analgesic effect than 50 mg of tramadol when administered before a mandibular third molar surgery.


Subject(s)
Analgesics, Opioid/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Ketorolac/therapeutic use , Molar, Third/surgery , Tooth, Impacted/surgery , Tramadol/therapeutic use , Analgesics , Double-Blind Method , Humans , Pain Measurement , Pain, Postoperative
7.
Br J Oral Maxillofac Surg ; 53(9): 796-804, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26316017

ABSTRACT

The aim of this systematic review and meta-analysis was to assess the risk of surgical wound infection and the adverse effects of amoxicillin in healthy patients who required excision of third molars. We identified eligible reports from searches of PubMed, Medline®, the Cochrane Library, Imbiomed, LILACS, and Google Scholar. Studies that met our minimum requirements were evaluated using inclusion and exclusion criteria and the Oxford Quality Scale. Those with a score of 3 or more on this Scale were included and their data were extracted and analysed. For evaluation of the risk of infection the absolute risk reduction, number needed to treat, and 95% CI were calculated. For evaluation of the risk of an adverse effect the absolute risk increase, number needed to harm, and 95% CI were calculated using the Risk Reduction Calculator. Each meta-analysis was made with the help of the Mantel-Haenszel random effects model, and estimates of risk (OR) and 95% CI were calculated using the Review Manager 5.3, from the Cochrane Library. A significant risk was assumed when the lower limit of the 95% CI was greater than 1. Probabilities of less than 0.05 were accepted as significant. The results showed that there was no reduction in the risk of infection when amoxicillin was given before or after operation compared with an untreated group or placebo. In conclusion, this study suggests that amoxicillin given prophylactically or postoperatively does not reduce the risk of infection in healthy patients having their third molars extracted.


Subject(s)
Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Surgical Wound Infection , Amoxicillin/adverse effects , Anti-Bacterial Agents/adverse effects , Humans , Molar, Third/surgery , Risk , Safety
8.
Water Environ Res ; 83(2): 162-72, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21449478

ABSTRACT

For activated sludge modeling purposes, the methods used to evaluate the readily biodegradable chemical oxygen demand (RBCOD) in the influents are by biological or via physicochemical assays. However, there has not been sufficient wide comparison between these methods. The main goal of this study was to investigate the performance of the main chemical oxygen demand (COD) fractionation protocols, considering a representative wastewater in the context of tropical and developing countries. Different physicochemical characterization procedures, respirometric tests, and chemical analyses were performed. The fate of the soluble COD in the aeration tanks was studied. The results of the study showed that a marked difference may exist, in municipal wastewaters, between the estimates of the RBCOD fractions measured by respirometry and by any of the physicochemical methods. The evaluated influent showed a rather large fraction of COD that was passing the filters without being rapidly biodegradable, but which was removed quickly by enmeshment in the bioflocs. The consequences of such divergences and behavior are discussed.


Subject(s)
Biodegradation, Environmental , Bioreactors , Oxygen Consumption/physiology , Waste Disposal, Fluid , Environmental Monitoring , Water Pollutants, Chemical
9.
Rev. méd. Chile ; 131(8): 847-856, ago. 2003.
Article in Spanish | LILACS | ID: lil-356050

ABSTRACT

BACKGROUND: The Chilean Society of Respiratory Diseases (SER) developed guidelines for the empirical treatment of community acquired pneumonia (CAP). AIM: To evaluate the degree of adherence to antibiotic treatment recommended by SER guidelines and its influence on medical outcomes. PATIENTS AND METHODS: We prospectively evaluated 453 consecutive immunocompetent adults (mean age +/- SD: 69 +/- 19 years) hospitalized for CAP. Patients were stratified according to the Pneumonia Severity Index (PSI), and initial antibiotic regimen was classified as being consistent or inconsistent with the SER guidelines. Rate of medical complications, switch therapy rate, length of stay (LOS), and 30 days mortality were compared between those treated consistently or inconsistently with the SER guidelines. RESULTS: Adherence to SER guidelines was 46 per cent. Patients treated consistently with the SER guidelines were older (mean age +/- SD: 72 +/- 16 v/s 65 +/- 20 years), had more comorbidities (84 v/s 69 per cent) and a higher proportion belonged to the high-risk PSI categories (69 v/s 49 per cent). There were no significant differences in medical complication rate, switch therapy rate or LOS between both groups. Adherence to SER guidelines did not affect mortality after adjusting for PSI and for prognostic factors associated with 30 days mortality by multivariate analysis. CONCLUSIONS: The degree of adherence to antibiotic treatment recommended by SER guidelines was moderate and they were applied mainly in patients with high risk CAP. This fact can explain the lack of evidence of improved medical outcome in patients treated according to SER guidelines.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Guideline Adherence , Pneumonia, Bacterial/drug therapy , Multivariate Analysis , Chile/epidemiology , Prospective Studies , Cohort Studies , Hospitalization , Community-Acquired Infections/drug therapy , Community-Acquired Infections/mortality , Pneumonia, Bacterial/mortality , Prognosis
10.
Drugs Exp Clin Res ; 25(2-3): 133-41, 1999.
Article in English | MEDLINE | ID: mdl-10370876

ABSTRACT

An intervention study was performed to evaluate the influence of a Mediterranean diet, a high fat diet, and their supplementation with red wine in moderate amounts, on biochemical, physiological, and clinical parameters related to atherosclerosis and other chronic diseases. For 3 months two groups of 21 male volunteers each, received either a Mediterranean diet or a high fat diet; during the second month, red wine was added isocalorically, 240 ml/day. Participants were kept under close medical and nutritional surveillance. At days 0, 30, 60 and 90, clinical, physiological and biochemical evaluations were made. Plasma vitamin C was significantly decreased in the high fat diet group compared to the Mediterranean diet group. After wine supplementation to the Mediterranean diet, a significant 13.5% increase in plasma vitamin C was observed. Furthermore, when wine was added vitamin E decreased significantly in plasma, 15% in the high fat diet and 26% in the Mediterranean diet. Total plasma antioxidant capacity (total antioxidant reactivity) increased 28% above basal levels in the Mediterranean diet group, but not in the high fat diet group. In both groups, wine induced a marked increase in total antioxidant reactivity above basal levels, 56% and 23%, respectively. Oxidative DNA damage, detected as 8-hydroxydeoxyguanosine (8-OHdG) levels in blood leukocyte DNA, was markedly increased by the high fat diet; however, it was strongly reduced, to approximately 50% basal values, after wine supplementation, both in the high fat diet and Mediterranean diet groups. Endothelial function, evaluated noninvasively as flow-mediated vascular reactivity of the brachial artery, was suppressed by the high fat diet, and was normal after wine supplementation. These effects are attributed to oxidative stress associated with a high fat diet, and to the elevated plasma antioxidant capacity associated with wine consumption and the Mediterranean diet. The results presented support the following conclusions: a high fat diet induces oxidative stress; a diet rich in fruits and vegetables enhances antioxidant defenses; wine supplementation to a high fat or a Mediterranean diet increases plasma antioxidant capacity, decreases oxidative DNA damage, and normalizes endothelial function.


Subject(s)
Antioxidants/analysis , DNA Damage/drug effects , Diet, Atherogenic , Dietary Fats , Flavonoids , Phenols/blood , Phenols/metabolism , Polymers/metabolism , Wine/analysis , Adult , Arteriosclerosis/prevention & control , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Humans , Lipid Metabolism , Male , Oxidative Stress/drug effects , Polyphenols
11.
Rev Biol Trop ; 47(4): 929-37, 1999 Dec.
Article in Spanish | MEDLINE | ID: mdl-11021311

ABSTRACT

Stilestrongylus peromysci n. sp. collected from Peromyscus difficilis (Hidalgo state, México), differs from other species in the genus in number of the spines (30) in the synlophe (both sexes) and because the eighth ray arises from the root of the ninth ray; S. hidalguensis n. sp. parasitised Peromyscus sp. and differs from all other congeneric species in the presence of 24 spines in the male synlophe and in the arrangement of the bursal rays (2-2-1 in the right lobe and 2-3 in the left lobe). A key to the species of Stilestrongylus is provided.


Subject(s)
Peromyscus/parasitology , Strongylida/isolation & purification , Animals , Female , Male , Mexico , Rats , Strongylida/anatomy & histology , Strongylida/classification
12.
Z Naturforsch C J Biosci ; 46(7-8): 647-55, 1991.
Article in English | MEDLINE | ID: mdl-1776995

ABSTRACT

Chloramphenicol is a widely used antibiotic with low levels of toxicity. However, scanning electron microscopy revealed morphological changes in human erythrocytes when they interacted in vitro with therapeutical concentrations of chloramphenicol. To explain this shape change, a study concerned with the possible interactions of this antibiotic with bilayers built-up of phospholipids located in either side of the red cell membrane was performed by X-ray diffraction. Results indicated that chloramphenicol was unable to perturb in any significant extent the structure of the phospholipids under study. The only noticeable effects were phase transitions produced to dimyristoylphosphatidylethanolamine bilayers.


Subject(s)
Chloramphenicol/chemistry , Erythrocyte Membrane/ultrastructure , Erythrocytes/ultrastructure , Lipid Bilayers/chemistry , Phospholipids/chemistry , Chloramphenicol/pharmacology , Erythrocyte Membrane/drug effects , Erythrocytes/drug effects , Humans , Membrane Lipids/blood , Microscopy, Electron, Scanning , Phospholipids/blood , X-Ray Diffraction/methods
13.
Z Naturforsch C J Biosci ; 45(3-4): 265-72, 1990.
Article in English | MEDLINE | ID: mdl-2363791

ABSTRACT

Pentachlorophenol (PCP) is a widely used and highly toxic fungicide. Its toxicity is mainly expressed at the cell membrane level. It is, therefore, of interest to test its ability to alter the lipid bilayer organization. The present study was performed by X-ray diffraction techniques on dimyristoylphosphatidylethanolamine (DMPE) and dimyristoylphosphatidylcholine (DMPC) bilayers and by fluorescence on DMPC liposomes. These two phospholipids are respectively found at the inner and outer monolayers of human erythrocyte membranes. Each type of phospholipid was made to interact with different concentrations of the sodium form of PCP in absence and in presence of water. It was found that PCP significantly affected the structure of both phospholipids, being the damage much higher in DMPC bilayers.


Subject(s)
Chlorophenols , Dimyristoylphosphatidylcholine , Lipid Bilayers , Pentachlorophenol , Phosphatidylethanolamines , Environmental Pollutants , Molecular Conformation , Spectrometry, Fluorescence , X-Ray Diffraction
SELECTION OF CITATIONS
SEARCH DETAIL
...